Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
Caris Life Sciences, a leader in oncology diagnostics, has announced plans to go public with a $400 million initial public offering (IPO) on the Nasdaq stock exchange. The move comes after 17 years in business and follows significant growth in the company's clinical case volume and revenue.
In a dramatic and unexpected development, the Department of Health and Human Services (HHS) under newly confirmed Secretary Robert F. Kennedy Jr. has removed all 17 sitting members of the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). This decision marks a significant shift in the nation's vaccine policy landscape and has sent shockwaves through the medical community.
UnitedHealth Group, the healthcare giant, is actively considering bids for its Latin American operations, signaling a significant strategic shift in its global portfolio. The move comes as the company faces financial challenges and seeks to refocus its efforts on core markets.
Pharmaceutical giant Pfizer has unveiled a new educational initiative focused on sickle cell disease (SCD), despite recent setbacks in its SCD treatment pipeline. The company's UK branch has launched a two-part video series titled "Our Sickle Cell Story: It's Time to Listen," aimed at sharing the experiences of individuals living with SCD and improving public understanding of the condition.
Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have reported promising long-term data for their complement regulator Empaveli (pegcetacoplan) in rare kidney diseases, potentially strengthening the drug's position ahead of an upcoming FDA decision.
Sanofi and Regeneron have announced positive Phase IV data for their blockbuster biologic Dupixent, demonstrating its efficacy in treating atopic dermatitis in patients with darker skin tones. The study results, released on Sunday, highlight the drug's potential to address a significant unmet need in dermatological care for diverse patient populations.
Omada Health, a digital chronic condition management company, went public on Friday, marking the second recent initial public offering (IPO) in the digital health sector. This development, coupled with Hinge Health's IPO last month, suggests a potential revival in the industry after a period of limited public offerings.
In a significant move within the pharmaceutical industry, GlaxoSmithKline (GSK) has announced the appointment of Sanjay Gurunathan, M.D., as the new head of vaccine and infectious disease research and development. This strategic hire marks a notable shift in leadership between two major players in the global pharmaceutical landscape.
The U.S. Food and Drug Administration (FDA) has taken decisive action to restrict the use of prominent PD-1 inhibitors in certain stomach cancer patients, marking a significant shift in the treatment landscape for gastric and esophageal cancers.Merck's Keytruda (pembrolizumab) and Bristol Myers Squibb's Opdivo (nivolumab) have both seen their indications narrowed for the treatment of advanced or metastatic gastric, gastroesophageal junction (GEJ), and esophageal cancers. The FDA now limits the use of these immunotherapies to patients whose tumors express PD-L1, a protein that helps cancer cells evade the immune system.
Omada Health, a digital chronic condition management company, went public on Friday, marking the second recent initial public offering (IPO) in the digital health sector. The company's debut on the Nasdaq stock exchange under the ticker symbol "OMDA" comes just weeks after virtual musculoskeletal company Hinge Health's IPO, potentially signaling a resurgence of interest in public offerings for digital health firms.
Concentra Biosciences, owned by Tang Capital Partners, has made another strategic move in its ongoing series of acquisitions, agreeing to purchase Elevation Oncology for $0.36 per share. This latest deal comes on the heels of Concentra's recent buyouts of Kronos Bio and Allakos, solidifying its position as an aggressive player in the biotech M&A landscape.
WuXi Biologics, a leading contract development and manufacturing organization (CDMO), has announced the groundbreaking of a new state-of-the-art microbial production facility in Chengdu, China. The 95,000-square-meter (1.2 million-square-foot) plant is set to become a cornerstone in the company's expansion strategy, capitalizing on the growing global demand for microbial-derived biopharmaceuticals.
